It becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), the Digital Spatial Profiling revolution has started.
To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.
Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.
B cells are to the forefront of cancer immunotherapy. Discover how!
See our case study or download our white paper!
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by themobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
Our newly validated M2 suppression assay is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.
Syngeneic tumor models are becoming invaluable for preclinical development and evaluation of immuno-based therapies. They are primordial for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.
Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models.
Explicyte set up and validated a robust real-time neutrophil migration assay, which allows for time-lapse monitoring and analysis of chemotactic driven neutrophil migration across an optically clear filter membrane.
In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March.